Organigram Holdings Inc. (TSE:OGI - Free Report) - Investment analysts at Atb Cap Markets reduced their FY2028 earnings estimates for Organigram in a research report issued to clients and investors on Wednesday, August 13th. Atb Cap Markets analyst F. Gomes now expects that the company will earn $0.14 per share for the year, down from their prior estimate of $0.15. The consensus estimate for Organigram's current full-year earnings is $0.16 per share.
Organigram Stock Performance
Shares of TSE:OGI traded down C$0.05 on Friday, reaching C$2.09. 36,194 shares of the company's stock were exchanged, compared to its average volume of 173,841. The firm has a market capitalization of C$258.20 million, a price-to-earnings ratio of -4.42, a PEG ratio of 0.42 and a beta of 1.13. Organigram has a fifty-two week low of C$1.22 and a fifty-two week high of C$2.84. The business's 50-day moving average is C$1.95 and its two-hundred day moving average is C$1.78. The company has a quick ratio of 2.62, a current ratio of 3.36 and a debt-to-equity ratio of 3.07.
Organigram Company Profile
(
Get Free Report)
Organigram Inc is a Canadian licensed producer of cannabis products. Organigram focuses on producing exceptional, indoor-grown cannabis for patients and adult recreational consumers, as well as developing global business partnerships.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Organigram, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organigram wasn't on the list.
While Organigram currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access